Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyc-116. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 8/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 8/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 13/20 | 1.00 |
| ▸ | CDK4 | P11802 | 9/20 | 1.00 |
| ▸ | CDK9 | P50750 | 8/20 | 1.00 |
| ▸ | JAK2 | O60674 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 4/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 1.00 |
| ▸ | WEE1 | P30291 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyc-116 SCHEMBL2074998 | 1.00 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4167448 | 0.91 | CDK2 (0.83) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4172272 | 0.90 | CDK2 (0.81) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2073867 | 0.89 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2076109 | 0.89 | CDK2 (0.84) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4167442 | 0.89 | CDK2 (0.80) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4176578 | 0.87 | CDK2 (0.77) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4165922 | 0.87 | CDK2 (0.79) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2076667 | 0.87 | CDK2 (0.79) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2075969 | 0.87 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| US-20250163456-A1 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | NIPPON MEDICAL SCHOOL FOUNDATION (JP) | 2025-05-22 | — | — | US | claimed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250146080-A1 | METHODS FOR OVERCOMING TAZEMETOSTAT-RESISTANCE IN CANCER PATIENTS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | claimed |
| EP-4484555-A1 | VIRAL VECTOR PRODUCIBILITY ENHANCER AND METHOD FOR PRODUCING VIRAL VECTOR | NIPPON MEDICAL SCHOOL FOUNDATION (JP) | 2025-01-01 | — | — | EP | claimed |
| CN-118871575-A | Enhancer for viral vector production and method for producing viral vector | 学校法人日本医科大学 | 2024-10-29 | — | — | CN | claimed |
| WO-2024186883-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-DRIVEN CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-12 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| US-20220288102-A1 | Compounds for Hepatitis B Treatment | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-15 | — | — | US | claimed |
| US-20220288025-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE | UNM RAINFOREST INNOVATIONS (US) | 2022-09-15 | — | — | US | claimed |
| WO-2022187554-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | claimed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4009975-A1 | COMPOUNDS FOR HEPATITIS B TREATMENT | Agency for Science, Technology and Research (SG) | 2022-06-15 | — | — | EP | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114555089-A | Compounds for the treatment of hepatitis B | 新加坡科技研究局 | 2022-05-27 | — | — | CN | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | AURKA 249/4885AURKB 320/4885KDR 3236/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | AURKA 249/4885AURKB 320/4885KDR 3236/4885 |
| US-20220288102-A1 | Compounds for Hepatitis B Treatment | TUBAL3, TUBB3, NAT10 | AURKA 380/4885AURKB 87/4885KDR 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.